SCHEMBL16631510

SCHEMBL16631510

CC#Cc1[nH]c(=O)ccc1[C@@H]1O[C@H](CO)C(O)[C@@H]1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 4/20 0.36
SLC28A3 Q9HAS3 2/20 0.36
SLC28A1 O00337 1/20 0.36
SLC28A2 O43868 1/20 0.36
SLC29A1 Q99808 1/20 0.36
DYRK1A Q13627 1/20 0.35
PAX8 Q06710 1/20 0.35
LGALS8 O00214 6/20 0.35
LGALS3 P17931 2/20 0.34
LGALS9 O00182 1/20 0.34
LGALS1 P09382 1/20 0.34
LGALS7; LGALS7B P47929 1/20 0.34
PRKCA P17252 3/20 0.33
PRKD3 O94806 1/20 0.32
PRKCG P05129 1/20 0.32
PRKCB P05771 1/20 0.32
PRKCH P24723 1/20 0.32
PRKCI P41743 1/20 0.32
PRKCE Q02156 1/20 0.32
PRKCQ Q04759 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631572 0.88 SLC5A2 (0.37) SLC5A2SLC28A3SLC28A1SLC28A2SLC29A1
SCHEMBL16631240 0.87 SLC28A1 (0.41) SLC5A2SLC28A3SLC28A1SLC28A2SLC29A1
SCHEMBL16631827 0.86 DYRK1A (0.33) SLC5A2DYRK1APAX8PRKCAPRKD3
SCHEMBL16631848 0.85
SCHEMBL18079912 0.84 SLC28A3 (0.37) SLC5A2SLC28A3SLC28A1SLC28A2SLC29A1
SCHEMBL16631232 0.83 TK2 (0.35) SLC5A2LGALS8LGALS3LGALS9LGALS1
SCHEMBL16631505 0.83 PYGL (0.33) SLC5A2LGALS8LGALS3
SCHEMBL16631431 0.82 SLC28A1 (0.39) SLC5A2SLC28A3SLC28A1SLC28A2SLC29A1
SCHEMBL16631379 0.81 SLC28A3 (0.38) SLC5A2SLC28A3SLC28A1SLC28A2SLC29A1
SCHEMBL16631217 0.81 PYGL (0.33) SLC5A2SLC28A3SLC28A1SLC28A2SLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 SLC5A2 3235/4885SLC28A3 2337/4885SLC28A1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.